Outbreak of Carbapenem-Resistant Pseudomonas aeruginosa Producing VIM-8, a Novel Metallo-β-Lactamase, in a Tertiary Care Center in Cali, Colombia

ABSTRACT The prevalence of imipenem resistance among Pseudomonas aeruginosa isolates at a 195-bed tertiary care medical center in Cali, Colombia, rose from 2% in 1996 to 28% in 1997 and to over 40% in 2003. Many isolates showed high-level multiresistance, and phenotypic characterization suggested the spread of a predominant strain with minor variants. Sixty-six resistant isolates collected between February 1999 and July 2003 from hospitalized patients (n = 54) and environmental samples (n = 12) were subjected to a fuller analysis. Genetic fingerprints were compared by pulsed-field gel electrophoresis (PFGE) of SpeI-digested genomic DNA, and blaIMP and blaVIM genes were sought by PCR. PFGE and serotyping indicated that 52 of the 66 isolates belonged to a single strain, with 82% similarity; the PFGE pattern for this organism was designated pattern A. Two further pairs of isolates represented single strains; the remaining nine isolates were unique, and in the case of one isolate, no satisfactory PFGE profile could be obtained. The pattern A isolates were mostly of serotype O12 and were highly resistant to imipenem (MICs, 32 to >256 μg/ml), with this resistance decreased eightfold or more in the presence of EDTA. They yielded amplicons with blaVIM-specific primers, and sequencing of DNA from a representative isolate revealed blaVIM-8, a novel allele with three polymorphisms compared with the sequence of blaVIM-2. Two of these nucleotide changes were silent, but the third determined a Thr139Ala substitution. Only 4 of 13 resistant isolates (2 clinical isolates and 2 environmental isolates) assigned to other PFGE types carried blaVIM alleles, whereas the others were less multiresistant and mostly had lower levels of imipenem resistance (MICs, ≤32 μg/ml) which was not significantly reduced by EDTA. No blaIMP alleles were detected. During 2003, when the environmental study was undertaken, serotype O12 isolates with blaVIM were recovered from sinks and stethoscopes in the most-affected units, although not from the hands of staff; the problem declined once these reservoirs were disinfected and hygienic precautions were reinforced.

[1]  E. Bruck,et al.  National Committee for Clinical Laboratory Standards. , 1980, Pediatrics.

[2]  R. W. Davis,et al.  Separation of large DNA molecules by contour-clamped homogeneous electric fields. , 1986, Science.

[3]  T. Pitt Epidemiological typing of Pseudomonas aeruginosa. , 1988, European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology.

[4]  T. Pitt,et al.  Resistance mechanisms of multiresistant serotype 012 Pseudomonas aeruginosa isolated in Europe. , 1990, Journal of Antimicrobial Chemotherapy.

[5]  J. Waitz Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically , 1990 .

[6]  S. Ichiyama,et al.  Multifocal outbreaks of metallo-beta-lactamase-producing Pseudomonas aeruginosa resistant to broad-spectrum beta-lactams, including carbapenems , 1996, Antimicrobial agents and chemotherapy.

[7]  M. Rué,et al.  Evaluation of outcome for intubated patients with pneumonia due to Pseudomonas aeruginosa. , 1996, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[8]  T. Pitt,et al.  Epidemiologically related and unrelated strains of Pseudomonas aeruginosa serotype O12 cannot be distinguished by phenotypic and genotypic typing. , 1997, The Journal of hospital infection.

[9]  Pan‐Chyr Yang,et al.  Persistence of a Multidrug-ResistantPseudomonas aeruginosa Clone in an Intensive Care Burn Unit , 1998, Journal of Clinical Microbiology.

[10]  N. Woodford,et al.  Carbapenemase-producing Pseudomonas aeruginosa in UK , 1998, The Lancet.

[11]  Yasuaki Yamada,et al.  Rapid Detection and Evaluation of Clinical Characteristics of Emerging Multiple-Drug-Resistant Gram-Negative Rods Carrying the Metallo-β-Lactamase GeneblaIMP , 1998, Antimicrobial Agents and Chemotherapy.

[12]  G. Cornaglia,et al.  Appearance of IMP-1 metallo-β-lactamase in Europe , 1999, The Lancet.

[13]  Mary Jane Ferraro,et al.  Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically : approved standard , 2000 .

[14]  N. Woodford,et al.  Carbapenemases: a problem in waiting? , 2000, Current opinion in microbiology.

[15]  N. Woodford,et al.  Outbreak of Infections Caused by Pseudomonas aeruginosa Producing VIM-1 Carbapenemase in Greece , 2000, Journal of Clinical Microbiology.

[16]  S. Pournaras,et al.  Carbapenem-hydrolysing VIM-2 metallo- beta-lactamase in Pseudomonas aeruginosa from Greece. , 2000, The Journal of antimicrobial chemotherapy.

[17]  G. Cornaglia,et al.  Hospital outbreak of carbapenem-resistant Pseudomonas aeruginosa producing VIM-1, a novel transferable metallo-beta-lactamase. , 2000, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[18]  Ronald N. Jones,et al.  Characterization of Pseudomonas aeruginosa isolates: occurrence rates, antimicrobial susceptibility patterns, and molecular typing in the global SENTRY Antimicrobial Surveillance Program, 1997-1999. , 2001, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[19]  J. Wu,et al.  Metallo-β-Lactamases in ClinicalPseudomonas Isolates in Taiwan and Identification of VIM-3, a Novel Variant of the VIM-2 Enzyme , 2001, Antimicrobial Agents and Chemotherapy.

[20]  J. Andrews,et al.  Determination of minimum inhibitory concentrations. , 2001, The Journal of antimicrobial chemotherapy.

[21]  N. Gotoh,et al.  Carbapenem Resistance Mechanisms in Pseudomonas aeruginosa Clinical Isolates , 2001, Antimicrobial Agents and Chemotherapy.

[22]  J. Verhoef,et al.  Antimicrobial susceptibility of imipenem-resistant Pseudomonas aeruginosa. , 2002, The Journal of antimicrobial chemotherapy.

[23]  D. Livermore,et al.  bla VIM-2 Cassette-Containing Novel Integrons in Metallo-β-Lactamase-Producing Pseudomonas aeruginosa and Pseudomonas putida Isolates Disseminated in a Korean Hospital , 2002, Antimicrobial Agents and Chemotherapy.

[24]  Richard A. Moore,et al.  Nosocomial Outbreak of Carbapenem-Resistant Pseudomonas aeruginosa with a New blaIMP Allele, blaIMP-7 , 2002, Antimicrobial Agents and Chemotherapy.

[25]  H. Shin,et al.  Imipenem-EDTA Disk Method for Differentiation of Metallo-β-Lactamase-Producing Clinical Isolates of Pseudomonas spp. and Acinetobacter spp , 2002, Journal of Clinical Microbiology.

[26]  Ronald N. Jones,et al.  Molecular characterization of SPM-1, a novel metallo-beta-lactamase isolated in Latin America: report from the SENTRY antimicrobial surveillance programme. , 2002, The Journal of antimicrobial chemotherapy.

[27]  P. Hsueh,et al.  Antimicrobial susceptibilities among clinical isolates of extended-spectrum cephalosporin-resistant Gram-negative bacteria in a Taiwanese University Hospital. , 2002, The Journal of antimicrobial chemotherapy.

[28]  P. Nordmann,et al.  Emerging carbapenemases in Gram-negative aerobes. , 2002, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[29]  H. Giamarellou Prescribing guidelines for severe Pseudomonas infections. , 2002, The Journal of antimicrobial chemotherapy.

[30]  N. Woodford,et al.  IMP-1 carbapenemase detected in an Acinetobacter clinical isolate from the UK. , 2002, The Journal of antimicrobial chemotherapy.

[31]  A. Barth,et al.  Antibiotic resistance and molecular typing of Pseudomonas aeruginosa: focus on imipenem. , 2002, The Brazilian journal of infectious diseases : an official publication of the Brazilian Society of Infectious Diseases.

[32]  R. Scott,et al.  The global impact of drug resistance. , 2003, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[33]  E. Petinaki,et al.  Hospital outbreak of multiple clones of Pseudomonas aeruginosa carrying the unrelated metallo-beta-lactamase gene variants blaVIM-2 and blaVIM-4. , 2003, The Journal of antimicrobial chemotherapy.

[34]  Yasuaki Yamada,et al.  Clinical and bacteriological characteristics of IMP-type metallo-beta-lactamase-producing Pseudomonas aeruginosa. , 2003, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[35]  A. Gales,et al.  Dissemination in distinct Brazilian regions of an epidemic carbapenem-resistant Pseudomonas aeruginosa producing SPM metallo-beta-lactamase. , 2003, The Journal of antimicrobial chemotherapy.

[36]  Ronald N. Jones,et al.  Genetic characterization of a novel metallo-beta-lactamase gene, blaIMP-13, harboured by a novel Tn5051-type transposon disseminating carbapenemase genes in Europe: report from the SENTRY worldwide antimicrobial surveillance programme. , 2003, The Journal of antimicrobial chemotherapy.

[37]  Ronald N. Jones,et al.  Emergence of an IMP-like metallo-enzyme in an Acinetobacter baumannii clinical strain from a Brazilian teaching hospital. , 2003, Diagnostic microbiology and infectious disease.